Medrio launches three-tier Early Adopter Program for clinical trial software
Medrio's Early Adopter Program offers three tiers of discounted access to clinical trial software, with Level 2 participants running...
Editor's Choice
AI Adoption in Clinical Trials Slowed by Regulatory Gaps, Not Technology Limits
Regulatory gaps and organizational challenges slow AI adoption in clinical trials despite proven 90% reductions in data aggregation time.
Cecolin 9 Shows Six-Month Data in Single-Dose HPV Trial vs Gardasil 9
Cecolin 9 shows six-month immunogenicity data in single-dose HPV trial against Gardasil 9, with final results expected in 2028.
Kos Biotechnology Partners Funds Golden Age Health for Asia Rare Disease Access
Kos Biotechnology Partners funds Golden Age Health to accelerate rare disease access in Asia, closing treatment delays for patients...
Citius Oncology Reports LYMPHIR Unit Sales, Vial Orders for Q4 2026
Citius Oncology reports preliminary LYMPHIR unit sales and vial orders for Q4 2026, signaling commercial momentum in the cutaneous...
EIK1001 achieves 63.1% response rate in untreated stage 4 lung cancer
EIK1001 achieves 63.1% response rate in untreated stage 4 lung cancer, with strong disease control across histology subtypes in...
ORKA-001 achieves 61% complete skin clearance in Phase 2b psoriasis trial
ORKA-001 achieves 61% complete skin clearance in Phase 2b psoriasis trial, with potential for once-yearly dosing in maintenance treatment.
WCG’s Activation Intelligence Targets the Document Conflict That Quietly Kills Your Startup Timeline
WCG's new Activation Intelligence tool claims to cut 20+ hours of rework per study launch by catching document conflicts...
The Enzyme Nobody Watched: How Mitapivat’s Phase 3 Win Rewrites the Rules for Sickle Cell Drug Development
Mitapivat hit a 40.6% hemoglobin response rate in the RISE UP Phase 3 trial, and the endpoint strategy that...
RELATIVITY-047’s Five-Year Data Just Made LAG-3 Biomarker Selection a Clinical Trial Design Imperative
RELATIVITY-047's 5-year survival data and LAG-3-high CD8+ T cell biomarker findings signal a shift in how immuno-oncology trials must...